Panbela Therapeutics, Inc. Common Stock

PBLA

Market cap $3.86M

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares.

MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “Public Warrants”) at a purchase price of $2.06 per share and associated Public Warrants and $2.059 per pre-funded warrant and associated Public Warrants. The pre-funded warrants have an exercise price of $0.001 per share. The Public Warrants have an exercise price of $2.06 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The Public Warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events.

MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024. The work reflects the Company's on-going collaboration with Johns Hopkins University School of Medicine.

Panbela Therapeutics (NASDAQ: PBLA ) stock is falling on Monday after the clinical-stage biopharmaceutical company revealed the pricing of a public offering for its shares. Panbela Therapeutics is selling 4,375,000 shares of its common stock for $2.06 each.

MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “Common Warrants”) at a purchase price of $2.06 per share and associated Common Warrants. The Common Warrants will have an exercise price of $2.06 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The Common Warrants do not have any alternative cashless exercise or other provisions to adjust their exercise price beyond customary proportionate adjustments for recapitalizations and similar events. The offering is expected to close on or about January 31, 2024, subject to customary closing conditions.

MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has reached 50% enrollment for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at  https://clinicaltrials.gov/ct2/show/NCT05254171  .

A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma. A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma.

MINNEAPOLIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will implement the previously announced and stockholder approved 1-for-20 reverse split of its common stock. The reverse stock split will be effective as of the morning of January 18, 2024, and the company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “PBLA.” The CUSIP number for the common stock following the reverse stock split will be 69833W404.

MINNEAPOLIS, Dec. 21, 2023 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 2,556,000 shares of its common stock, in the aggregate, to exercise outstanding warrants at the existing exercise price of $0.78 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.0 million, before deducting financial advisory fees. The exercisability of the new warrants and any resulting issuance of the shares underlying the new warrants are subject to stockholder approval in accordance with Nasdaq rules.